# A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)

> **NCT06050954** · PHASE2 · WITHDRAWN · sponsor: **Fox Chase Cancer Center**

## Conditions studied

- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** Pembrolizumab (200mg)
- **DRUG:** Pembrolizumab (400mg)
- **DIAGNOSTIC_TEST:** Monitoring

## Key facts

- **NCT ID:** NCT06050954
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09
- **Primary completion:** 2027-01
- **Final completion:** 2032-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change in standard of care.
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06050954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06050954, "A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06050954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*